Cencora, Inc. (COR) Earnings Call Transcripts

Cencora, Inc.'s Latest Earnings Call - Q3 FY2026

In Q3 FY2026, Cencora, Inc. reported revenue of $84.8 billion, a 5% increase year-over-year, and adjusted EPS growth of 12%, driven by strong performance in its U.S. Healthcare Solutions segment and the One Oncology acquisition. Management raised its fiscal 2026 adjusted EPS guidance to a range of $17.75 to $17.95, reflecting confidence in continued execution and robust portfolio strength. The company also highlighted a 17% growth in adjusted operating income, supported by strategic investments and share repurchases totaling $1 billion.

Reported metrics

Guidance from management

Cencora raised its fiscal 2026 adjusted EPS guidance to $17.75-$17.95, while maintaining revenue guidance for its U.S. Healthcare Solutions segment in the lower half of the 4%-6% growth range. International Healthcare Solutions revenue growth is now expected to be approximately 8%.

What management said

Yes. Thanks, Eva. Lisa, thank you for the question. And yes, we're really excited that Eva is here with us to help us continue to execute at a very high level. On your question about 2027. So Eva gave some modeling guidance that will help everyone kind of estimate where we should be for the year. I'm not going to take it any further than that. But I will reiterate kind of what I was meaning to say in the remarks is t...

Okay. Just to add on the utilization trends, right? We did see a sequential rebound in the utilization trends from the March quarter. Strong sales in specialty products, as I said previously, to health systems and physician providers. Oncology clearly is the larger but retina also contributed to that sequential improvement. .

What analysts pressed on

Analysts expressed concerns about the impact of manufacturer list price reductions on revenue growth and the potential headwinds from regulatory changes in the ASP rules. There were questions about the sustainability of growth in the specialty segment and the integration of One Oncology.

Main topics on the call

• Revenue Growth and Segment Performance — Cencora's revenue reached $84.8 billion, up 5% year-over-year, with the U.S. Healthcare Solutions segment contributing $74.9 billion. Management noted, "Our revenue growth was supported by strength in specialty across bo...
• Guidance Increase — Management raised its fiscal 2026 adjusted EPS guidance from $17.70-$17.90 to $17.75-$17.95, citing strong year-to-date performance. This adjustment reflects confidence in the company's execution and growth trajectory.
• Specialty Pharmaceutical Platform — Cencora's specialty platform is positioned to support innovation and patient care, with management stating, "Our differentiated specialty pharmaceutical platform uniquely positions us to support innovation and patient ca...
• Digital Transformation Initiatives — The company is leveraging AI for demand forecasting to enhance operational efficiency, with management emphasizing, "Our teams are using AI to better anticipate product needs across our network and identify key factors d...

Read the full Cencora, Inc. transcript (Q3 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 75 Cencora, Inc. earnings call transcripts on record, spanning January 9, 2020 to August 5, 2026. Based on this history, Cencora, Inc. reports quarterly. The most recent call on file is dated August 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

COR

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

75

First call

January 9, 2020

Most recent

August 5, 2026

Reporting cadence

quarterly